Key Highlights: Implications: Qdenga’s positive SEC opinion moves India close to its first widely available dengue vaccine, with import approval tied to a rapid post‑marketing s...
Key Highlights: Implications: The dispersible format gives Akums a clear differentiation edge in the acute migraine space, directly addressing nausea and swallowing difficulties that often...
Key Highlights: Implications: The partnership lets Zydus scale its semaglutide franchise while tapping Torrent’s strong chronic-care reach, accelerating GLP‑1 penetration without stretchin...
Key Highlights: Implications: The deal lets Lupin plug directly into India’s fast‑building GLP‑1 market without its own development risk, while helping Zydus rapidly widen semaglutid...
Key Highlights: Implications: The 7-ACA facility directly strengthens India’s antibiotic supply chain by localizing production of a critical cephalosporin KSM, reducing exposure to import ...
Key Highlights: Implications: The new indication firmly positions durvalumab as a frontline immunotherapy option in advanced liver cancer, giving oncologists a more con...
Key Highlights: Implications: This curbs aggressive GLP-1 marketing (e.g., Ozempic/Wegovy), protecting India’s $115M diabetes/obesity segment from off-label hype amid 101M diabetics....
Key Highlights: Implications: Lilly’s pricing gamble carves a high-end niche, outpacing semaglutide generics from local players through clinical edge and brand power. This sets up fi...
Key Highlights: Implications: Emcure grabs massive share in India’s exploding CKD/anemia market, challenging Sun Pharma/Jubilant while locking in transplant dominance through Roche&#...
Key Highlights: Implications: Extensior catapults Abbott into the GLP-1 frenzy, grabbing prime shelf space before generics from Eris/Natco crash prices by half—think explosive Tier-2 growt...
